Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Lars Fruergaard Jørgensen

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Wegovy maker Novo Nordisk could make prices flexible—without cutting them—to persuade more health systems to cover the weight-loss drugs

Weight-loss drug Wegovy faces high demand, limited supply, and tricky health care systems to navigate.

inkl

Read news from The Economist, FT, and more,
with one subscription

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Revealed: obesity jab maker discussed targeting benefit claimants with UK government

Drug firm Novo Nordisk proposed singling out those most likely to return to work with its weight-loss injection

The Guardian - UK

Germany considers banning Ozempic exports, including to U.S.

Germany considers banning Ozempic exports, including to U.S.

Germany exports Ozempic to the EU and the U.S., Karl Broich, president of the German Federal Institute for Drugs and Medical Devices, told Der Spiegel.

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk threatens to expand in US in row over EU rules

Novo Nordisk's CEO doesn't like proposed new EU rules that would cut the period for which drugmakers enjoy exclusivity for their products from 10 years to eight years.

1 Pharma Stock That Could Help You Become a Millionaire

1 Pharma Stock That Could Help You Become a Millionaire

Prominent pharma player Novo Nordisk (NVO) posted solid revenue and earnings growth in fiscal 2022. The company’s long-term growth is expected to be spearheaded by its immensely popular GLP-1 drug Wegovy. Given the potential of its current portfolio of drugs and drugs under research, investing in this stock could be…

1

People

Dipanjan BanchurSince

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Medical Pharmaceuticals

the Department of Health

Novo Nordisk AS

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

243,699 stories

102,260 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play